| CAS NO: | 180064-38-4 |
| 包装 | 价格(元) |
| 10mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 200mg | 电议 |
| 500mg | 电议 |
| Cas No. | 180064-38-4 |
| 别名 | 1-羟基-2-(咪唑并[1,2-A]吡啶-3-基)乙烷-1,1-双膦酸,YM-529 |
| Canonical SMILES | OC(P(O)(O)=O)(P(O)(O)=O)CC1=CN=C2C=CC=CN21 |
| 分子式 | C9H12N2O7P2 |
| 分子量 | 322.15 |
| 溶解度 | Water: 5 mg/mL (15.52 mM and warming); DMSO:< 1 mg/mL (insoluble or slightly soluble) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Minodronic acid (YM-529) is a third-generation bisphosphonate that directly and indirectly prevents proliferation, induces apoptosis, and inhibits metastasis of various types of cancer cells. Minodronic acid (YM-529) is an antagonist of purinergic P2X2/3 receptors involved in pain[1][2]. P2X2/3[2] [1]. Sato K, et al. A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo. Br J Cancer. 2006 Nov 20;95(10):1354-61. [2]. Tanaka M, et al. Minodronic acid induces morphological changes in osteoclasts at bone resorption sites and reaches a level required for antagonism of purinergic P2X2/3 receptors. J Bone Miner Metab. 2018 Jan;36(1):54-63. |
m.cnreagent.com